Blog
RSS FeedPosted by Michael Wonder on 19 Oct 2022
Senator Collins, Representative Eshoo decry Medicare coverage rejection of Alzheimer’s drugs
18 October 2022 - “It’s not CMS’ job to deny the use under the Medicare program of an FDA-approved drug.” – ...
Posted by Michael Wonder on 10 Oct 2022
Mental health funding of £1.8 million welcomed by NICE and MHRA to explore regulation of digital mental health tools
10 October 2022 - NICE and the MHRA have been awarded £1.8 million funding by Wellcome over three years to explore ...
Posted by Michael Wonder on 27 Sep 2022
More medicines for New Zealanders, thanks to Government’s Budget boost
28 September 2022 - Health Minister Andrew Little is welcoming news that two more important medicines are set to be ...
Posted by Michael Wonder on 27 Sep 2022
Half of GPs say staying open is financially unsustainable as Medicare rebate fails
28 September 2022 - Staying in general practice is financially unsustainable for almost half of the nation’s GPs due to ...
Posted by Michael Wonder on 27 Sep 2022
PHARMAC seeking feedback on nusinersen sodium and adrenaline auto-injectors funding
28 September 2022 - PHARMAC has initiated two consultations today, seeking feedback on the funding of two different medicines that we've ...
Posted by Michael Wonder on 16 Aug 2022
GPs demand action to fix ‘disintegrating’ Medicare
17 August 2022 - Doctors have issued the federal government with an urgent demand for more Medicare funding, warning general ...
Posted by Michael Wonder on 17 Jul 2022
COVID antivirals available by telehealth phone consultation
16 July 2022 - Medicare will cover a long consultation by a GP for the purpose of prescribing COVID-19 antivirals, with ...
Posted by Michael Wonder on 06 Jul 2022
PHARMAC opens door to funding Keytruda in 'biggest step forward in treatment of lung cancer'
6 July 2022 - Keytruda has been called a 'miracle' drug, and there's a glimmer of hope now for those ...
Posted by Michael Wonder on 06 Jul 2022
PHARMAC considering funding new medicines for lung cancer
6 July 2022 - PHARMAC is seeking proposals from pharmaceutical suppliers for medicines that could treat New Zealanders with lung ...
Posted by Michael Wonder on 30 Jun 2022
From FDA to MHRA: are drug regulators for hire?
29.June 2022 - Patients and doctors expect drug regulators to provide an unbiased, rigorous assessment of investigational medicines before they hit ...
Posted by Michael Wonder on 28 Jun 2022
The Innovative Medicines Fund - good news for patients but has an opportunity been missed to be more ambitious?
27 June 2022 - NHS England and Improvement has announced the launch of the Innovative Medicines Fund. The ABPI’s Director ...
Posted by Michael Wonder on 16 Jun 2022
Subsidy for medicine for Duchenne muscular dystrophy expires
16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...
Posted by Michael Wonder on 15 Jun 2022
Shionogi signs agreement with NHS England to begin an innovative subscription payment model for reimbursement of its antibiotic, Fetcroja (cefiderocol)
15 June 2022 - Shionogi recognises the UK’s leadership role in introducing the world’s first fully ‘delinked’ pilot reimbursement model; pull ...
Posted by Michael Wonder on 15 Jun 2022
England’s Innovative Medicines Fund hits another milestone
15 June 2022 - Just like the Cancer Drugs Fund, the time-limited fund for the most promising cancer drugs introduced ...
Posted by Michael Wonder on 15 Jun 2022
PHARMAC announces first round of medicine funding decisions following $191 million pharmaceutical budget increase
15 June 2022 - PHARMAC today announces the first round of changes to medicines funding following its $191 million pharmaceutical ...